ADVB חוב כולל להון Advanced Biomed Inc

Advanced Biomed Inc (ADVB) aims for the global distribution of microfluidic systems to combat oncology. Company management is focused on validating test efficacy to ensure their inclusion in standard medical protocols. The business is currently developing high-precision tumor screening tools, and the individual debt-to-equity ratio stands at 0.08. This chart illustrates the exchange price action based on this metric.

This ratio determines the share of borrowed funds within the financing structure, comparing total liabilities to net assets to assess financial stability. The debt-to-equity dynamics are critical for Advanced Biomed Inc. (ADVB), as liquidity shortages and losses incurred during the development of diagnostic platforms make the business highly dependent on external leverage.